JAK1 and myelofibrosis: Baricitinib and ruxolitinib, both targeting JAK1 and JAK2 which are the dominant kinases downstream of IL-6, have been approved for the treatment of myelofibrosis and rheumatoid arthritis, respectively (Garbers et al., 2018).